EA200801274A1 - Лечение субъектов с хронической почечной недостаточностью ( хпн ) с применением соединений лантана - Google Patents

Лечение субъектов с хронической почечной недостаточностью ( хпн ) с применением соединений лантана

Info

Publication number
EA200801274A1
EA200801274A1 EA200801274A EA200801274A EA200801274A1 EA 200801274 A1 EA200801274 A1 EA 200801274A1 EA 200801274 A EA200801274 A EA 200801274A EA 200801274 A EA200801274 A EA 200801274A EA 200801274 A1 EA200801274 A1 EA 200801274A1
Authority
EA
Eurasian Patent Office
Prior art keywords
crf
treatment
lanthane
subjects
compounds
Prior art date
Application number
EA200801274A
Other languages
English (en)
Other versions
EA015171B1 (ru
Inventor
Рэймонд Дэнис Прат
Исобэл Вэбстер
Стэфэн Джп Дэммент
Original Assignee
Шир Интернэшнл Лайсенсинг Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37114439&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200801274(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Шир Интернэшнл Лайсенсинг Б.В. filed Critical Шир Интернэшнл Лайсенсинг Б.В.
Publication of EA200801274A1 publication Critical patent/EA200801274A1/ru
Publication of EA015171B1 publication Critical patent/EA015171B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Лечение субъекта с симптомами хронической почечной недостаточности (ХПН), не страдающего, однако, почечной недостаточностью в терминальной стадии (ПНТС), может осуществляться путем перорального введения фармацевтического состава, содержащего в качестве активного ингредиента терапевтически эффективное количество нетоксичного соединения лантана. Введение соединения лантана может предотвращать прогрессирование ХПН, излечивать кальциноз мягких тканей и вторичный гиперпаратиреоз.
EA200801274A 2005-11-09 2006-11-07 Лечение субъектов с хроническим заболеванием почек с применением соединений лантана EA015171B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/272,563 US20070104799A1 (en) 2005-11-09 2005-11-09 Treatment of chronic kidney disease (CKD) subjects using lanthanum compounds
PCT/US2006/060598 WO2007056721A2 (en) 2005-11-09 2006-11-07 Treatment of chronic kidney disease (ckd) subjects using lanthanum compounds

Publications (2)

Publication Number Publication Date
EA200801274A1 true EA200801274A1 (ru) 2008-10-30
EA015171B1 EA015171B1 (ru) 2011-06-30

Family

ID=37114439

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200801274A EA015171B1 (ru) 2005-11-09 2006-11-07 Лечение субъектов с хроническим заболеванием почек с применением соединений лантана

Country Status (26)

Country Link
US (1) US20070104799A1 (ru)
EP (1) EP1785142B1 (ru)
JP (1) JP2009514986A (ru)
KR (1) KR101318067B1 (ru)
CN (1) CN101304753B (ru)
AR (1) AR057876A1 (ru)
AT (1) ATE492284T1 (ru)
AU (1) AU2006311286B2 (ru)
BR (1) BRPI0619667A2 (ru)
CA (1) CA2629036C (ru)
CY (1) CY1111609T1 (ru)
DE (1) DE602006019043D1 (ru)
DK (1) DK1785142T3 (ru)
EA (1) EA015171B1 (ru)
ES (1) ES2362201T3 (ru)
HK (1) HK1102545A1 (ru)
IL (1) IL190860A0 (ru)
MY (1) MY147391A (ru)
NO (1) NO20082536L (ru)
NZ (1) NZ567519A (ru)
PL (1) PL1785142T3 (ru)
PT (1) PT1785142E (ru)
SI (1) SI1785142T1 (ru)
TW (1) TWI388329B (ru)
WO (1) WO2007056721A2 (ru)
ZA (1) ZA200804853B (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0924533A2 (pt) * 2009-05-15 2015-06-30 Natco Pharma Ltd Processo para a preparação de carbonato de latânio di-hidratado
US20110033529A1 (en) * 2009-08-06 2011-02-10 Durga Prasad Samantaray Oral pharmaceutical paricalcitol formulations
EP2569418B1 (en) 2010-05-12 2016-11-02 RegenMed (Cayman) Ltd. Bioactive renal cells
US8263119B2 (en) * 2010-12-01 2012-09-11 Shire Llc Capsule formulations containing lanthanum compounds
CN103127041A (zh) * 2012-02-23 2013-06-05 南京卡文迪许生物工程技术有限公司 含有醋酸镧的药物组合物及其制备方法和用途
CN103120654A (zh) * 2012-02-23 2013-05-29 南京卡文迪许生物工程技术有限公司 醋酸镧或其水合物治疗血磷酸盐过多症的用途
CN103127042A (zh) * 2013-03-07 2013-06-05 尹颖 一种稳定高效的降磷组合物
CN103127043A (zh) * 2013-03-07 2013-06-05 尹颖 一种稳定高效的降磷组合物
JP2022516567A (ja) * 2019-01-04 2022-02-28 ケイデンス ファーマ アーセー リン吸着剤とビタミンｋとの併用療法
CN111620363A (zh) * 2020-06-13 2020-09-04 南京卡文迪许生物工程技术有限公司 一种四水合碳酸镧的制备方法及其产品
CN111686008A (zh) * 2020-07-20 2020-09-22 温州海鹤药业有限公司 一种混煎中药去磷工艺

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2640570B2 (ja) * 1992-01-13 1997-08-13 ファイザー インク． 強度が増加した錠剤の製造
CA2128199C (en) * 1994-07-15 1997-02-04 Bernard Charles Sherman Stable solid pharmaceutical compositions containing enalapril maleate
GB9506126D0 (en) * 1995-03-25 1995-05-10 Johnson Matthey Plc Pharmaceutical composition and method
US20010014352A1 (en) * 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
US6160016A (en) * 1999-12-22 2000-12-12 Wisconsin Alumni Research Foundation Phosphorus binder
GB0015745D0 (en) * 2000-06-27 2000-08-16 Shire Holdings Ag Treatment of bone diseases
JP4515030B2 (ja) * 2001-04-23 2010-07-28 アノーメッド インコーポレイティド 腎臓結石疾患の予防のための希土類化合物の使用
US20040161474A1 (en) * 2002-05-24 2004-08-19 Moerck Rudi E. Rare earth metal compounds methods of making, and methods of using the same
US7381428B2 (en) * 2003-08-26 2008-06-03 Shire International Licensing B.V. Stabilized lanthanum carbonate compositions
EP2792363B1 (en) 2003-08-26 2016-06-29 Shire Biopharmaceuticals Holdings Ireland Limited Pharmaceutical formulation comprising lanthanum compounds
KR20070054191A (ko) * 2004-07-27 2007-05-28 샤이어 파마세우티컬, 인크. 란탄 하이드록시 카보네이트를 이용한 고인산증 치료 방법
WO2006044657A2 (en) * 2004-10-15 2006-04-27 Altairnano, Inc. Phosphate binder with reduced pill burden
US20060177415A1 (en) * 2004-11-01 2006-08-10 Burke Steven K Once a day formulation for phosphate binders
US20060276534A1 (en) * 2005-03-17 2006-12-07 Amgen Inc. Methods of decreasing calcification

Also Published As

Publication number Publication date
EP1785142A1 (en) 2007-05-16
AU2006311286B2 (en) 2012-08-23
SI1785142T1 (sl) 2011-07-29
PT1785142E (pt) 2011-03-23
DK1785142T3 (da) 2011-03-14
EP1785142B1 (en) 2010-12-22
AU2006311286A1 (en) 2007-05-18
CN101304753A (zh) 2008-11-12
CN101304753B (zh) 2012-12-12
ZA200804853B (en) 2014-01-29
TWI388329B (zh) 2013-03-11
DE602006019043D1 (de) 2011-02-03
JP2009514986A (ja) 2009-04-09
ATE492284T1 (de) 2011-01-15
HK1102545A1 (en) 2007-11-30
BRPI0619667A2 (pt) 2011-10-11
CA2629036A1 (en) 2007-05-18
NZ567519A (en) 2011-04-29
CY1111609T1 (el) 2015-10-07
WO2007056721A3 (en) 2007-10-25
NO20082536L (no) 2008-07-28
ES2362201T3 (es) 2011-06-29
MY147391A (en) 2012-11-30
KR20080071175A (ko) 2008-08-01
US20070104799A1 (en) 2007-05-10
EA015171B1 (ru) 2011-06-30
TW200727905A (en) 2007-08-01
KR101318067B1 (ko) 2013-10-15
CA2629036C (en) 2014-07-22
PL1785142T3 (pl) 2011-07-29
AR057876A1 (es) 2007-12-26
WO2007056721A2 (en) 2007-05-18
IL190860A0 (en) 2008-11-03

Similar Documents

Publication Publication Date Title
EA200801274A1 (ru) Лечение субъектов с хронической почечной недостаточностью ( хпн ) с применением соединений лантана
BRPI0513603A (pt) uso de hidroxicarbonato de lantánio e composição farmacêutica
DK1827386T3 (da) Orale sammensætninger til absorption af phosphor-forbindelser
EA201070544A1 (ru) Новый класс терапевтических веществ, усиливающих диффузию низкомолекулярных соединений
EA200801997A1 (ru) Новые соединения
EA200801275A1 (ru) Стабилизированные составы карбоната лантана
EA200970581A1 (ru) Кристаллическое твёрдое основание разагилина
NO20091260L (no) Kombinasjonsbehandling for diabetes mellitus
EA200701845A1 (ru) Рофлумиласт для лечения сахарного диабета
NO20065048L (no) Kontrastmidler for myocardial perfusjonsbilleddannelse.
MA29236B1 (fr) Prevention et traitement de troubles thromboemboliques
EA201100255A1 (ru) 5-алкинилпиримидины
MY151295A (en) Pyrimidyl indoline compound
EA201200968A1 (ru) Применение транс-кломифена для предотвращения или лечения диабета 2 типа у мужчин
EA201100254A1 (ru) Новые соединения
EA200970127A1 (ru) Модулятор рецепторов глюкокортикостероидов и способы его применения
EA200702336A1 (ru) ПРИМЕНЕНИЕ 24-норУДХК
CL2007001747A1 (es) Compuestos derivados de aril y heteroaril-etil-acilguanidina; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento y prevencion de la hipertension, insuficiencia cardiaca y afecciones renales entre otras.
WO2006047162A3 (en) Compositions and methods for treatment of disease caused by yersinia spp infection
EA200801890A1 (ru) Средство для лечения шума в ушах
WO2007116297A3 (en) Use of aminapthone for the preparation of a medicament for treating arteriophaties
EA201000990A1 (ru) Лечение дисменореи путем трансдермального введения нестероидных противовоспалительных лекарственных средств
WO2006124544A3 (en) Use of tyrosine kinase inhibitors in the treatment of metabolic disorders
WO2007116428A3 (en) Oral pharmaceutical composition containing cystine or cysteine with glutathione against oxidative stress resulting from haemodialysis
ITMI20032528A1 (it) Uso di cistina o di cisteina per la prevenzione e il

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG TJ TM

PC4A Registration of transfer of a eurasian patent by assignment